AnaptysBio expects $417M cash at year-end 2023; presents at JPM Healthcare Conference

ANAPTYSBIO, INC

Preliminary cash, cash equivalents, and investments of approximately $417M as of December 31, 2023.
Presentation at J.P. Morgan Healthcare Conference on January 8, 2024; full corporate overview furnished as Exhibit 99.1.
Audited FY2023 financials not yet available; preliminary estimate subject to adjustment.
Presentation details (pipeline, clinical data) not fully available in the provided exhibit excerpt.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.